Medical doctor specialized in General Medicine with a PhD in Epidemiology. More than ten years of experience with national infectious disease surveillance and vaccinology. Head of Vaccine Preventable Diseases group at Department of Infectious Disease Epidemiology and Prevention since 2010. The group works with the Danish childhood vaccination program, surveillance of vaccine preventable diseases, monitoring of vaccine uptake by use of the Danish Vaccination Register, which is an electronic immunization registry, vaccine effectiveness, register-based studies of determinants for vaccination uptake, invasive bacterial diseases, influenza, monitoring of mortality, tuberculosis and vector-borne diseases.For the European Center of Disease Prevention and Control (ECDC) I am serving as the National Focal Point for vaccine preventable as well as emerging and vectorborne diseases. I am part of the consortium of VENICE (Vaccine European New Integrated Collaboration Effort) and of SpIDnet2, investigating the impact of pneumococcal vaccination. These are networks, funded by ECDC, where vaccine experts from European countries share data and experiences.He is the author/co-author ~70 peer reviewed publications and has extensive teaching experience in vaccinology and infectious disease epidemiology, and have supervised co-workers, master students and at PhD level. Several years of experience from running large research projects in developing countries aiming to understand the natural history of and to improve the case management of diarrhoea and pneumonia.
February 14, 2017
“It is not surprising,” said Valentiner-Branth. “This is a special type of influenza, A H3N2, which particularly affects the elderly population and often requires hospitalisation.”Valentiner-Branth said that there has been an increase in the number of admissions to intensive care units compared to what is normal during the flu season...
February 07, 2015
“We unfortunately will not live up to the WHO’s goals. That will contribute to the continued spread of infectious disease in Denmark,” SSI spokesman Palle Valentiner-Branth told Politiken. SSI said that growing scepticism about vaccines and their side effects among parents is the direct reason that Denmark will not hit its measles elimination goal. “The MMR vaccine was introduced in 1987 and in the years between 2002 and 2005 we had almost fully eliminated one of the major childhood diseases – measles – from Denmark. But now we have a real problem because so many parents don’t get their children vaccinated,” Valentiner-Branth told Politiken...
Impact of 13-Valent Pneumococcal Conjugate Vaccination in Invasive Pneumococcal Disease Incidence and MortalityClinical Infectious Diseases
2014The impact of the 13-valent pneumococcal conjugate vaccine (PCV13) at the population level is unclear. We explored PCV13's effect in reducing invasive pneumococcal disease (IPD)–related morbidity and mortality, and whether serotype-specific changes were attributable to vaccination or expected as a part of natural, cyclical variations.
2010Pneumococcal infections have historically played a major role in terms of morbidity and mortality. We explored historical trends of invasive pneumococcal disease (IPD) and pneumococcal serotypes in a population exposed to limited antibiotic selective pressure and conjugate pneumococcal vaccination (PCV).
Pneumococcal Serotypes and Mortality following Invasive Pneumococcal Disease: A Population-Based Cohort StudyPLOS Medicine
2009Pneumococcal disease is a leading cause of morbidity and mortality worldwide. The aim of this study was to investigate the association between specific pneumococcal serotypes and mortality from invasive pneumococcal disease (IPD).
2008Diarrhoea is an important cause of death and illness among children in developing countries; however, it remains controversial as to whether diarrhoea leads to stunting. We conducted a pooled analysis of nine studies that collected daily diarrhoea morbidity and longitudinal anthropometry to determine the effects of the longitudinal history of diarrhoea prior to 24 months on stunting at age 24 months. Data covered a 20-year period and five countries. We used logistic regression to model the effect of diarrhoea on stunting. The prevalence of stunting at age 24 months varied by study (range 21–90%), as did the longitudinal history of diarrhoea prior to 24 months (incidence range 3.6–13.4 episodes per child-year, prevalence range 2.4–16.3%). The effect of diarrhoea on stunting, however, was similar across studies. The odds of stunting at age 24 months increased multiplicatively with each diarrhoeal episode and with each day of diarrhoea before 24 months (all P < 0.001). The adjusted odds of stunting increased by 1.13 for every five episodes (95% CI 1.07–1.19), and by 1.16 for every 5% unit increase in longitudinal prevalence (95% CI 1.07–1.25). In this assembled sample of 24-month-old children, the proportion of stunting attributed to ≥5 diarrhoeal episodes before 24 months was 25% (95% CI 8–38%) and that attributed to being ill with diarrhoea for ≥2% of the time before 24 months was 18% (95% CI 1–31%). These observations are consistent with the hypothesis that a higher cumulative burden of diarrhoea increases the risk of stunting.
Area of Expertise
Health Care - Facilities
Writing and Editing
Københavns Universitet : Philosophy, Epidemiology
Københavns Universitet : Medicine